


FIG. 1



PRODUCT-LIMIT SURVIVAL ESTIMATES
WITH NUMBER OF SUBJECTS AT RISK
+ CENSORED
SURVIVAL PROBABILITY
1.0
0.8
0.6
0.4
0.2
0.0
NO
YES
14
23
4
14
2
5
1
1
0
5
10
15
DEATH
MICK_USE —— NO - - - - YES

FIG. 2




PRODUCT-LIMIT SURVIVAL ESTIMATES
WITH NUMBER OF SUBJECTS AT RISK
+ CENSORED
SURVIVAL PROBABILITY
1.0
0.8
0.6
0.4
0.2
0.0
NO
YES
14
23
4
12
1
4
0
0
0.0
2.5
5.0
7.5
10.0
12.5
15.0
PROG
MICK_USE
NO
YES

FIG. 3

CONTINGENCY ANALYSIS OF G VS P BY SITE OF CA

MOSAIC PLOT



FREQ: COUNT

CONTINGENCY TABLE

SITE OF CA	G VS P		
COUNT TOTAL % COL % ROW %	g < p	g >= p	
BREAST	1 1.33 33.33 2.33	42 56.00 58.33 97.67	43 57.33
LUNG	2 2.67 66.67 6.25	30 40.00 41.67 93.75	32 42.67
	3 4.00	72 96.00	75

TESTS

N	DF	-LogLIKE	RSQUARE (U)
75	1	0.36499699	0.0290


TEST	CHISQUARE	PROB>CHISQ
LIKELIHOOD RATIO	0.730	0.3929
PEARSON	0.736	0.3910

FISHER'S EXACT TEST	PROB	ALTERNATIVE HYPOTHESIS
LEFT	0.3893	PROB(G VS P=g >= p; IS GREATER FOR SITE OF CA=BREAST THAN LUNG
RIGHT	0.9265	PROB(G VS P=g >= p; IS GREATER FOR SITE OF CA=LUNG THAN BREAST
2-TAIL	0.5721	PROB(G VS P=g >= p; IS DIFFERENT ACROSS SITE OF CA

FIG. 4

CONTINGENCY ANALYSIS OF G VS P BY SITE OF CA

MOSAIC PLOT



FREQ: COUNT

CONTINGENCY TABLE

SITE OF CA	G VS P		
COUNT TOTAL % COL % ROW %	g < p	g >= p	
BREAST	1 2.00 33.33 2.33	42 84.00 89.36 97.67	43 86.00
COLON	2 4.00 66.67 28.57	5 10.00 10.64 71.43	7 14.00
	3 6.00	72 94.00	50

TESTS

N	DF	-LogLIKE	RSQUARE (U)
50	1	2.4110080	0.2125


TEST	CHISQUARE	PROB>CHISQ
LIKELIHOOD RATIO	4.822	0.0281*
PEARSON	7.353	0.0067*

FISHER'S EXACT TEST	PROB	ALTERNATIVE HYPOTHESIS
LEFT	0.0479*	PROB(G VS P=g >= p; IS GREATER FOR SITE OF CA=BREAST THAN COLON
RIGHT	0.9982	PROB(G VS P=g >= p; IS GREATER FOR SITE OF CA=COLON THAN BREAST
2-TAIL	0.0479*	PROB(G VS P=g >= p; IS DIFFERENT ACROSS SITE OF CA

FIG. 5

CONTINGENCY ANALYSIS OF G VS P BY SITE OF CA

MOSAIC PLOT



FREQ: COUNT

CONTINGENCY TABLE

SITE OF CA	G VS P: g < p	G VS P: g >= p	
COUNT TOTAL % COL % ROW %			
BREAST	1 1.22 20.00 2.33	42 51.22 54.55 97.67	43 52.44
COLON+LUNG	4 4.88 80.00 10.26	35 42.68 45.45 89.74	39 47.56
	5 6.10	77 93.90	82


TESTS

N	DF	-LogLIKE	RSQUARE (U)
82	1	1.1847456	0.0629

TEST	CHISQUARE	PROB>CHISQ
LIKELIHOOD RATIO	2.369	0.1237
PEARSON	2.247	0.1339

FISHER'S EXACT TEST	PROB	ALTERNATIVE HYPOTHESIS
LEFT	0.1507	PROB(G VS P=g >= p; IS GREATER FOR SITE OF CA=BREAST THAN COLON+LUNG
RIGHT	0.9789	PROB(G VS P=g >= p; IS GREATER FOR SITE OF CA=COLON+LUNG THAN BREAST
2-TAIL	0.1860	PROB(G VS P=g >= p; IS DIFFERENT ACROSS SITE OF CA

FIG. 6


BEST PROPRIETARY
7
6
5
4
3
2
1
0
-1
COLON
LUNG
SITE



BEST GENERIC
14
12
10
8
6
4
2
0
COLON
LUNG
SITE

FIG. 7




FIG. 8





FIG. 9



LEGEND:	ND: DATA NOT DISPLAYED		NS: NOT SENSITIVE	
CISPLATIN	10.0	DOXORUBICIN	3.5	DOXIL	1.2
4HC (CYTOXAN)	8.4	DANORUBICIN	3.1	BLEOMYCIN	1.1
SUNIFINIB	7.0	VINCRELBINE	3.1	VINCRISTINE	0.9
OXALIPLATIN	6.7	IRINOTECAN	2.6	CCNU	0.8
CARBOPLATIN	6.0	4HI(IFOSFAMIDO)	2.6	ETOPOSIDE	0.8
MELPHALAN	5.3	TAXOLERE	2.3	GEMCITABINE	0.8
VIDAZA	4.3	TAXOL	1.6	METHOTREXATE	0.8
DACTINOMYCIN	4.0	TEMOZOLOMIDE	1.5	TARCEVA	0.7
VELCADE	3.8	GLEEVEC (IMATINIB)	1.5	ALIMTA	0.6
SORAFENIB	3.8	PROCARBAZINE	1.3	DACARBAZINE	0.6
EPIRUBICIN	3.8	VINBLASTINE	1.2	5-FLUOROURACIL	0.3

4HI(IFOSFAMIDE)+EPIRUBICIN	3.2	GEMCITABINE+TAXOTERE	2.4
4HI(IFOSFAMIDE)+DOXORUBICIN+DACARBAZINE	2.5	METHOTREXATE+VINBLASTINE	2.2

FIG. 10